home / stock / cmvlf / cmvlf quote
Last: | $2.60 |
---|---|
Change Percent: | 100.0% |
Open: | $0 |
Close: | $2.60 |
High: | $0 |
Low: | $0 |
Volume: | 40 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.6 | $0 | $2.6 | $0 | $0 | 40 | 04-18-2024 |
$2.6 | $2.6 | $2.6 | $2.6 | $2.6 | 500 | 04-02-2024 |
$2.59 | $2.48 | $2.59 | $2.59 | $2.48 | 400 | 03-21-2024 |
$2.59 | $0 | $2.59 | $0 | $0 | 1 | 03-18-2024 |
$2.59 | $2.59 | $2.59 | $2.59 | $2.59 | 100 | 03-14-2024 |
$2.63 | $2.75 | $2.63 | $2.79 | $2.63 | 400 | 03-08-2024 |
$2.35 | $2.42 | $2.35 | $2.42 | $2.35 | 300 | 03-05-2024 |
$2.56 | $2.46 | $2.56 | $2.56 | $2.46 | 200 | 03-01-2024 |
$2.66 | $2.66 | $2.66 | $2.66 | $2.66 | 200 | 02-27-2024 |
$2.8 | $2.71 | $2.8 | $2.8 | $2.71 | 500 | 02-21-2024 |
$3.09 | $3.04 | $3.09 | $3.09 | $3.04 | 200 | 02-08-2024 |
$2.95 | $2.8744 | $2.95 | $2.95 | $2.8744 | 300 | 01-29-2024 |
$2.73 | $2.68 | $2.73 | $2.73 | $2.68 | 1,000 | 01-19-2024 |
$2.64 | $2.63 | $2.64 | $2.64 | $2.63 | 500 | 01-17-2024 |
$2.93 | $2.84 | $2.93 | $2.93 | $2.84 | 200 | 01-08-2024 |
$2.92 | $2.92 | $2.92 | $2.92 | $2.92 | 700 | 01-05-2024 |
$3 | $2.98 | $3 | $3 | $2.98 | 200 | 01-04-2024 |
$2.93 | $2.93 | $2.93 | $2.93 | $2.93 | 145 | 01-03-2024 |
$2.99 | $3.03 | $2.99 | $3.03 | $2.99 | 200 | 01-01-2024 |
$2.99 | $3.03 | $2.99 | $3.03 | $2.99 | 200 | 12-29-2023 |
News, Short Squeeze, Breakout and More Instantly...
Cellectis Romainville Ord Company Name:
CMVLF Stock Symbol:
OTCMKTS Market:
This novel editing approach might unlock new strategies for the treatment of metabolic and neurological diseases Non-viral circular ssDNA delivery associated to TALEN® gene editing allows high levels of gene insertion in long-term repopulating HSPCs NEW YORK, April 22, ...
NEW YORK, April 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a new ...
NEW YORK, April 08, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that preliminary data exp...